Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Federal Trade Commission
Fuji
Baxter
Johnson and Johnson
Express Scripts
Chubb
Cipla
Queensland Health

Generated: October 22, 2018

DrugPatentWatch Database Preview

Abbvie Company Profile

« Back to Dashboard

What is the competitive landscape for ABBVIE, and when can generic versions of ABBVIE drugs launch?

ABBVIE has ninety approved drugs.

There are eighty-nine US patents protecting ABBVIE drugs.

Summary for Abbvie
US Patents:89
Tradenames:78
Ingredients:65
NDAs:90
Drug Master File Entries: 1
Patent Litigation for Abbvie: See patent lawsuits for Abbvie

Drugs and US Patents for Abbvie

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie PLACIDYL ethchlorvynol CAPSULE;ORAL 010021-007 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie ULTANE sevoflurane LIQUID;INHALATION 020478-001 Jun 7, 1995 AN RX Yes Yes 6,074,668*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-002 Nov 5, 2004 AB RX Yes Yes 6,277,405 ➤ Try a Free Trial Y ➤ Try a Free Trial
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004 AB RX Yes No 7,041,319 ➤ Try a Free Trial Y ➤ Try a Free Trial
Abbvie VICODIN acetaminophen; hydrocodone bitartrate TABLET;ORAL 088058-001 Jan 7, 1983 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 RX Yes Yes 8,685,984 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Abbvie

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie MAVIK trandolapril TABLET;ORAL 020528-002 Apr 26, 1996 4,933,361 ➤ Try a Free Trial
Abbvie Endocrine Inc LUPRON DEPOT-PED leuprolide acetate INJECTABLE;INJECTION 020263-006 Jan 21, 1994 4,954,298 ➤ Try a Free Trial
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-003 Oct 26, 1984 5,212,326*PED ➤ Try a Free Trial
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-002 Nov 5, 2004 5,145,684 ➤ Try a Free Trial
Abbvie Endocrine Inc LUPRON DEPOT-PED leuprolide acetate INJECTABLE;INJECTION 020263-002 Apr 16, 1993 4,917,893 ➤ Try a Free Trial
Abbvie Endocrine Inc LUPRON DEPOT-PED leuprolide acetate INJECTABLE;INJECTION 020263-004 Apr 16, 1993 5,575,987 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ABBVIE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 250 mg ➤ Subscribe 2004-05-03
➤ Subscribe Delayed-release Capsules 45 mg ➤ Subscribe 2009-09-02
➤ Subscribe Extended-release Tablets 2 mg/180 mg and 2 mg/240 mg ➤ Subscribe 2007-11-09
➤ Subscribe Tablets 100 mg/25 mg ➤ Subscribe 2008-12-23
➤ Subscribe Extended-release Tablets 4 mg/ 240 mg ➤ Subscribe 2007-07-24
➤ Subscribe Tablets 100 mg ➤ Subscribe 2010-12-21
➤ Subscribe Tablets 400 mg and 600 mg ➤ Subscribe 2010-05-10
➤ Subscribe Injection 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials ➤ Subscribe 2008-11-28
➤ Subscribe Tablets 145 mg ➤ Subscribe 2007-10-19
➤ Subscribe Capsules 4 mcg ➤ Subscribe 2008-08-25
➤ Subscribe Tablets 5 mg/200 mg ➤ Subscribe 2005-05-27
➤ Subscribe Gel 1.62% ➤ Subscribe 2012-04-06
➤ Subscribe Injection 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial ➤ Subscribe 2009-08-04
➤ Subscribe Extended-release Tablet 500 mg ➤ Subscribe 2010-12-06
➤ Subscribe Extended-release Tablets 500 mg ➤ Subscribe 2005-02-08
➤ Subscribe Delayed-release Capsules 135 mg ➤ Subscribe 2009-09-01
➤ Subscribe Extended-release Tablets 1 mg/240 mg ➤ Subscribe 2008-02-20
➤ Subscribe Oral Solution 80 mg/20 mg per mL ➤ Subscribe 2014-06-19
➤ Subscribe Tablets 1 mg, 2 mg and 4 mg ➤ Subscribe 2004-10-04
➤ Subscribe Capsules 100 mg ➤ Subscribe 2012-10-31
➤ Subscribe Tablets 48 mg ➤ Subscribe 2008-07-01
➤ Subscribe Capsules 1 mcg and 2 mcg ➤ Subscribe 2008-10-14
➤ Subscribe Tablets 2.5 mg/200 mg ➤ Subscribe 2006-02-24
➤ Subscribe Gel Metered-dose Pump 1% ➤ Subscribe 2008-12-19
➤ Subscribe Gel 1.62% (1.25 g and 2.5 g packets) ➤ Subscribe 2013-06-19
➤ Subscribe Injection 2 mg/mL, 10 mL vial ➤ Subscribe 2009-08-12

Supplementary Protection Certificates for Abbvie Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB10/012 United Kingdom ➤ Try a Free Trial PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
/2017 Austria ➤ Try a Free Trial PRODUCT NAME: PIBRENTASVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1213 (MITTEILUNG) 20170728
C/GB01/044 United Kingdom ➤ Try a Free Trial PRODUCT NAME: THE COMBINATION OF THE ACTIVE INGREDIENTS RITONAVIR AND LOPINAVIR; REGISTERED: CH 55649 20001213; UK EU/1/01/172/001 20010320; UK EU/1/01/172/002 20010320; UK EU/1/01/172/003 20010320
2203431/01 Switzerland ➤ Try a Free Trial BEI DER ANMELDUNG WURDE DER INHABER IRRTUEMLICH DOPPELT ERFASST.
2017 00049 Denmark ➤ Try a Free Trial PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/17/1213 20170728
C/GB95/010 United Kingdom ➤ Try a Free Trial PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
US Army
Argus Health
Cerilliant
US Department of Justice
Boehringer Ingelheim
QuintilesIMS
Covington
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.